ADPT — Adaptogenics Health Income Statement
0.000.00%
Last trade - 00:00- CA$0.57m
- CA$0.42m
- CA$0.00m
Annual income statement for Adaptogenics Health, fiscal year end - March 31st, CAD millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 0 | 0 | 0.001 |
| Cost of Revenue | |||
| Gross Profit | — | — | 0 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Total Operating Expenses | 0.141 | 0.271 | 0.115 |
| Operating Profit | -0.141 | -0.271 | -0.114 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -0.141 | -0.266 | -0.147 |
| Net Income After Taxes | -0.141 | -0.266 | -0.147 |
| Net Income Before Extraordinary Items | |||
| Net Income | -0.141 | -0.266 | -0.147 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -0.141 | -0.266 | -0.147 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.009 | -0.016 | -0.009 |
| Dividends per Share |